Princeton Portfolio Strategies Group LLC grew its holdings in GlaxoSmithKline PLC (NYSE:GSK) by 5.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 30,796 shares of the pharmaceutical company’s stock after acquiring an additional 1,607 shares during the quarter. Princeton Portfolio Strategies Group LLC’s holdings in GlaxoSmithKline PLC were worth $1,328,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. FMR LLC boosted its holdings in GlaxoSmithKline PLC by 5.9% in the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after acquiring an additional 1,389,238 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after purchasing an additional 564,519 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of GlaxoSmithKline PLC by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after purchasing an additional 4,935,900 shares during the last quarter. Hotchkis & Wiley Capital Management LLC raised its stake in shares of GlaxoSmithKline PLC by 4.3% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after purchasing an additional 322,700 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after purchasing an additional 934,928 shares during the last quarter. 9.28% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently issued reports on the company. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Friday, June 16th. Citigroup Inc. cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. Zacks Investment Research cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, TheStreet cut GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $44.67.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down 0.12% on Friday, reaching $40.61. The company had a trading volume of 2,771,814 shares. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.54. The firm has a market capitalization of $99.25 billion, a P/E ratio of 39.35 and a beta of 1.03. The company’s 50-day moving average price is $40.07 and its 200 day moving average price is $41.64.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. On average, analysts expect that GlaxoSmithKline PLC will post $2.87 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a yield of 4.84%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 197.00%.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/10/08/glaxosmithkline-plc-gsk-holdings-raised-by-princeton-portfolio-strategies-group-llc.html.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.